Navigation Links
AMDL, Inc. New President & CEO Douglas MacLellan to Present at Rodman & Renshaw Annual Global Investment Conference November 12, 2008

TUSTIN, Calif., Nov. 6 /PRNewswire-FirstCall/ -- ( AMDL, Inc. (Amex: ADL), a leading vertically-integrated pharmaceutical company with major operations in China and the U.S., today announced its newly appointed Chairman and CEO Mr. Douglas MacLellan will present at Rodman & Renshaw's Annual Global Investment Conference taking place on Wednesday, November 12th, 2008 at the New York Palace Hotel in New York City.

Mr. MacLellan will provide an informative overview of AMDL's core business and growth strategy for its China specialty pharmaceuticals, in-vitro diagnostics and cancer therapeutic divisions. The Company has an aggressive and focused approach to capitalize on these three market sectors, positioning AMDL as one of most rapidly growing and highly-opportunistic micro-cap investment prospects in the vertically-integrated, specialty pharmaceutical sector.

In 2008 alone, AMDL met numerous operational milestones which include: securing more than $25 million in sales contracts for its best-selling HPE anti-aging product line; expanding AMDL's overall revenue opportunity for HPE by launching additional HPE product formulations; and successfully securing US FDA clearance for AMDL's ELISA DR-70(R) FDP cancer diagnostic test. The ELISA DR-70(R) FDP cancer diagnostic test is the first test to be cleared by the US FDA in over 25 years for the monitoring of colorectal cancer.

Attendees wishing to learn more about the Company can attend Mr. MacLellan's presentation which is scheduled at 9:55 a.m. EST in the Henry Salon, 5th Floor of the New York Palace Hotel. Additionally, interested investors can visit the Company's corporate website at or contact AMDL's investor relations department at 206.310.5323.

About AMDL:

Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a vertically integrated bio-pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The company employs over 400 people in the U.S. and China. The Company has an additional 4 pharmaceutical and diagnostic products under review by various regulatory authorities.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL, Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties related to the Company's access to additional capital, competition and dependence on key management.

AMDL Contact:

Kristine Szarkowitz

Director-Investor Relations

(206) 310-5323

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AMDL, Inc. Promotes CFO Akio Ariura to Chief Operating Officer and Expands Management Team
2. AMDL, Inc. Names Douglas MacLellan as Executive Chairman & CEO
3. AMDL, Inc.s President & CEO Mr. Gary Dreher Retires
4. AMDL, Inc. Named to Deloitte LLC Technology Fast 50
5. AMDL, Inc. Announces Strategic Realignment
6. AMDL, Inc. to Present at Maxim Group Growth Conference October 7, 2008
7. AMDL, Inc. Closes Private Placement of Convertible Notes
8. The Wall Street Transcript Interviews AMDL, Inc. CEO & President Gary Dreher for Fall Healthcare Issue
9. Rudd Report Highlights AMDL, Inc.s Latest Business Achievements; Supports 2008 Financial Guidance
10. AMDL, Inc. Retains Strategic Growth International Inc. as its Global Investor Relations Advisor
11. VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer
Post Your Comments:
(Date:11/30/2015)... MAGDEBURG, Germany , November 30, 2015 /PRNewswire/ ... in Vienna, Austria to be held ... NeuroRehabilitation (ECNR) in Vienna, Austria ... a wholly owned subsidiary of Vycor Medical, Inc. ("Vycor") (OTCQB: ... Internet-delivered NovaVision Therapy Suite at the 3rd European Congress ...
(Date:11/30/2015)... TIKVAH, Israel , Nov. 30, 2015 /PRNewswire/ ... a leading developer of adult stem cell technologies for neurodegenerative ... Ltd., has been awarded an additional grant of approximately $735,000 ... Scientist (OCS). This grant, the second this year, brings the ... approximately $1.8 million (approximately NIS7 million).  ...
(Date:11/27/2015)... ... 27, 2015 , ... Pittcon is pleased to announce the ... in symposia, oral sessions, workshops, awards, and posters. The core of the ... such as, but not limited to, biotechnology, biomedical, drug discovery, environmental, food science, ...
(Date:11/26/2015)... CHESHAM , England , November 26, ... Lightpoint Medical, an innovative medical device company specializing in ... Euro grant from the European Commission as part of the ... enabling the company to carry out a large-scale clinical trial ... -->      (Logo: , ...
Breaking Biology Technology:
(Date:11/26/2015)... , Nov. 26, 2015 Research and Markets ... "Capacitive Fingerprint Sensors - Technology and Patent Infringement ... --> --> Fingerprint sensors ... in smartphones. The fingerprint sensor vendor Idex forecasts an ... units in mobile devices and of the fingerprint sensor ...
(Date:11/19/2015)...  Although some 350 companies are actively involved in ... companies, according to Kalorama Information. These include Roche Diagnostics, Hologic, ... share of the 6.1 billion-dollar molecular testing market, according ... Molecular Diagnostic s .    ... by one company and only a handful of companies ...
(Date:11/17/2015)... , November 17, 2015 Paris ... 2015.   --> Paris from 17 ... DERMALOG, the biometrics innovation leader, has invented the first ... fingerprints on the same scanning surface. Until now two different ... Now one scanner can capture both on the same ...
Breaking Biology News(10 mins):